ESR1 and breast cancer: A Japanese study on a total of 167 BC patients revealed a correlation of higher IGFBP5 expression with poorer disease-free survival for patients with ERα-positive tumors, whereas no such correlation was found, when patients with ERα-negative tumors were included in the analysis (119).